SciELO - Scientific Electronic Library Online

 
vol.40 issue1Social context and moderate-severe food and nutritional insecurity in families with children aged 0-59 months, Paraíba, Brazil, 2017-2018Factors associated with microbiological contamination of chicken meat marketed in El Salvador author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Peruana de Medicina Experimental y Salud Publica

Print version ISSN 1726-4634

Abstract

RODRIGUEZ-TANTA, L. Yesenia et al. Characterization of adverse events to hydroxychloroquine, ivermectin, azithromycin and tocilizumab in patients hospitalized due to COVID-19 in a Peruvian Social Health Insurance hospital. Rev. perú. med. exp. salud publica [online]. 2023, vol.40, n.1, pp.16-24.  Epub Mar 28, 2023. ISSN 1726-4634.  http://dx.doi.org/10.17843/rpmesp.2023.401.11563.

Objective.

To characterize the adverse events (AEs) related to the off-label use of hydroxychloroquine (HQ), azithromycin (AZI), tocilizumab (TOB) and ivermectin (IVM) for the treatment of COVID-19 in hospitalized patients.

Materials and Methods.

We conducted a secondary cross-sectional analysis of the Peruvian Social Health Insurance (EsSalud) pharmacovigilance system database of AE notifications to HQ, AZI, TOB and IVM in the Edgardo Rebagliati Martins National Hospital from April to October 2020. Information was collected from digital medical records. We estimated AE reporting rates and evaluated their characteristics by drug type, time of occurrence, type by the affected organ-system, severity and causality.

Results.

We identified 154 notifications describing a total of 183 AE possibly related to HQ, AZI, TOB and IVM; the reporting rate was 8%. The median time of AE occurrence was 3 days (IQR: 2-5). Most were cardiovascular events; prolongation of the QT interval was the most frequent. Hepatobiliary AEs were mainly associated with TOB. Most cases were moderate, however, 10.4% were severe.

Conclusions.

We found AEs potentially associated with the use of HQ, AZI, TOB and IVM against COVID-19; cardiovascular events were the most frequent. Although AZI, HQ and IVM have known safety profiles, their use against COVID-19 could increase the occurrence of AE due to the risk factors inherent to this infection. Surveillance systems must be improved, especially those for TOB.

Keywords : Pharmacovigilance; COVID-19; Hydroxychloroquine; Azithromycin; Ivermectin; Tocilizumab.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )